Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1995 1
1997 1
1998 1
2000 1
2004 1
2005 2
2008 1
2010 1
2011 2
2012 1
2013 2
2014 2
2015 3
2017 1
2018 3
2019 2
2021 4
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
Locke JB, Pillar CM, Castanheira M, Carvalhaes CG, Andes D, Aram JA, Andrzejewski C, Bartizal K, Das AF, Sandison T, Thompson GR 3rd, Pappas PG. Locke JB, et al. Antimicrob Agents Chemother. 2024 Mar 25:e0158423. doi: 10.1128/aac.01584-23. Online ahead of print. Antimicrob Agents Chemother. 2024. PMID: 38526046 Free article.
Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the Phase 3 ReSTORE study based on the primary endpoints of day 14 global cure and 30-day all-cause mortality. ...This …
Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in …
Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia.
Miesel L, Cushion MT, Ashbaugh A, Lopez SR, Ong V. Miesel L, et al. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01992-20. doi: 10.1128/AAC.01992-20. Print 2021 Feb 17. Antimicrob Agents Chemother. 2021. PMID: 33318018 Free PMC article.
Rezafungin reduction of Candida CFU burden was generally greater with increasing drug concentrations (5, 10, or 20 mg/kg) and when rezafungin was administered closer to the time of fungal challenge (day -1, -3, or -5). ...These findings support phas …
Rezafungin reduction of Candida CFU burden was generally greater with increasing drug concentrations (5, 10, or 20 mg/kg) and …
Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.
Roepcke S, Passarell J, Walker H, Flanagan S. Roepcke S, et al. Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0091623. doi: 10.1128/aac.00916-23. Epub 2023 Nov 28. Antimicrob Agents Chemother. 2023. PMID: 38014945 Free PMC article.
Rezafungin is a chemically and metabolically stable echinocandin with a longer half-life than other echinocandins, allowing for a once-weekly intravenous infusion versus a daily infusion. Rezafungin is approved in the US for the treatment of candidemia …
Rezafungin is a chemically and metabolically stable echinocandin with a longer half-life than other echinocandins, allowing for a onc …
Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.
Lepak AJ, Zhao M, Andes DR. Lepak AJ, et al. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01572-18. doi: 10.1128/AAC.01572-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30181375 Free PMC article.
We evaluated the pharmacodynamics (PD) of rezafungin against 4 Candida auris strains, using the neutropenic mouse invasive candidiasis model. ...The stasis free-drug 24-h AUC/MIC target exposure for the group was 1.88, whereas the 1-log-kill free-drug 24-h AUC/MIC t …
We evaluated the pharmacodynamics (PD) of rezafungin against 4 Candida auris strains, using the neutropenic mouse invasive can …
Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Brüggemann RJ, Koster RA, Kampinga GA, Kosterink JG, van der Werf TS, Zijlstra JG, Touw DJ, Alffenaar JWC. Boonstra JM, et al. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01398-17. doi: 10.1128/AAC.01398-17. Print 2017 Dec. Antimicrob Agents Chemother. 2017. PMID: 28971861 Free PMC article. Clinical Trial.
Micafungin plasma concentrations were measured to estimate the pharmacokinetic properties of micafungin. MIC values for Candida isolates were determined to assess the probability of target attainment for patients. ...The median AUC(0-24)/MIC ratio was 5,684 (IQR, 4,325 to …
Micafungin plasma concentrations were measured to estimate the pharmacokinetic properties of micafungin. MIC values for Candida isola …
Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis.
Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B. Liu P, et al. Antimicrob Agents Chemother. 2013 Apr;57(4):1672-6. doi: 10.1128/AAC.02139-12. Epub 2013 Jan 18. Antimicrob Agents Chemother. 2013. PMID: 23335738 Free PMC article. Clinical Trial.
With the exclusion of the 240-kg patient, the median (minimum, maximum) age, weight, and body mass index (BMI) of 20 ICU patients were 57 (39, 78) years, 65 (48, 106) kg, and 23.3 (16.2, 33.8) kg/m(2), respectively. The average anidulafungin area under the curve over the 2 …
With the exclusion of the 240-kg patient, the median (minimum, maximum) age, weight, and body mass index (BMI) of 20 ICU patients were 57 (3 …
Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.
Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF. Wiederhold NP, et al. Antimicrob Agents Chemother. 2011 Jul;55(7):3254-60. doi: 10.1128/AAC.01750-10. Epub 2011 Apr 18. Antimicrob Agents Chemother. 2011. PMID: 21502632 Free PMC article.
Previous in vivo studies have reported caspofungin dose escalation to be effective against Candida glabrata with reduced susceptibility. We hypothesized that higher doses of caspofungin would be effective against invasive candidiasis caused by the more virule …
Previous in vivo studies have reported caspofungin dose escalation to be effective against Candida glabrata with reduced susce …
High-Dose Micafungin in Neonates and Young Infants with Invasive Candidiasis: Results of a Phase 2 Study.
Auriti C, Goffredo BM, Ronchetti MP, Piersigilli F, Cairoli S, Bersani I, Dotta A, Bagolan P, Pai MP. Auriti C, et al. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02494-20. doi: 10.1128/AAC.02494-20. Print 2021 Mar 18. Antimicrob Agents Chemother. 2021. PMID: 33558294 Free PMC article. Clinical Trial.
This study evaluated plasma levels, efficacy, and safety of micafungin at a dose of 8 mg/kg daily for a mean of 13.3 days (5.2 days) in 35 neonates and young infants with IC. Micafungin plasma concentrations were 5.70 mg/liter preadministration and 17.23, 15.59, and 10.27 …
This study evaluated plasma levels, efficacy, and safety of micafungin at a dose of 8 mg/kg daily for a mean of 13.3 days (5.2 days) …
Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis.
Kim YK, Lee J, Oh J, Rhee SJ, Shin SH, Yoon SH, Lee S, Kim HS, Yu KS. Kim YK, et al. Antimicrob Agents Chemother. 2019 May 24;63(6):e01960-18. doi: 10.1128/AAC.01960-18. Print 2019 Jun. Antimicrob Agents Chemother. 2019. PMID: 30910892 Free PMC article. Clinical Trial.
A pharmacokinetic model was developed using 301 fluconazole concentrations from 75 preterm infants with a baseline body weight (WT) ranging from 0.5 to 1.5 kg and an estimated glomerular filtration rate (eGFR) ranging from 12.9 to 58.5 ml/min/1.73 m(2) Eligible infants received a …
A pharmacokinetic model was developed using 301 fluconazole concentrations from 75 preterm infants with a baseline body weight (WT) ranging …
Population Pharmacokinetic Model and Optimal Sampling Strategies for Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM, van der Elst KC, Zijlstra JG, van der Werf TS, Alffenaar JWC, Touw DJ. Boonstra JM, et al. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0111322. doi: 10.1128/aac.01113-22. Epub 2022 Nov 15. Antimicrob Agents Chemother. 2022. PMID: 36377940 Free PMC article.
Candida bloodstream infections are associated with high attributable mortality, where early initiation of adequate antifungal therapy is important to increase survival in critically ill patients. ...
Candida bloodstream infections are associated with high attributable mortality, where early initiation of adequate antifungal therapy …
31 results